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Abstract: Background: This controlled clinical study aimed to investigate the impact of obesity on plasma
and tissue pharmacokinetics of meropenem. Methods: Obese (body mass index (BMI) ≥ 35 kg/m2) and
age-/sex-matched nonobese (18.5 kg/m2 ≥ BMI ≤ 30 kg/m2) surgical patients received a short-term
infusion of 1000-mg meropenem. Concentrations were determined via high performance liquid
chromatography-ultraviolet (HPLC-UV) in the plasma and microdialysate from the interstitial fluid
(ISF) of subcutaneous tissue up to eight h after dosing. An analysis was performed in the plasma
and ISF by noncompartmental methods. Results: The maximum plasma concentrations in 15 obese
(BMI 49 ± 11 kg/m2) and 15 nonobese (BMI 24 ± 2 kg/m2) patients were 54.0 vs. 63.9 mg/L (95%
CI for difference: −18.3 to −3.5). The volume of distribution was 22.4 vs. 17.6 L, (2.6–9.1), but the
clearance was comparable (12.5 vs. 11.1 L/h, −1.4 to 3.1), leading to a longer half-life (1.52 vs. 1.31
h, 0.05–0.37) and fairly similar area under the curve (AUC)8h (78.7 vs. 89.2 mg·h/L, −21.4 to 8.6).
In the ISF, the maximum concentrations differed significantly (12.6 vs. 18.6 L, −16.8 to −0.8) but not
the AUC8h (28.5 vs. 42.0 mg·h/L, −33.9 to 5.4). Time above the MIC (T > MIC) in the plasma and
ISF did not differ significantly for MICs of 0.25–8 mg/L. Conclusions: In morbidly obese patients,
meropenem has lower maximum concentrations and higher volumes of distribution. However, due to
the slightly longer half-life, obesity has no influence on the T > MIC, so dose adjustments for obesity
seem unnecessary.
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1. Introduction
Meropenem is a carbapenem with a broad spectrum of activity against Gram-positive and
Gram-negative bacteria, including multiresistant pathogens, and is therefore recommended for the
calculated therapy of patients with sepsis [1,2]. For the success of an anti-infective therapy and the
prevention of resistance development, the choice of the right antibiotic and the right duration of
therapy, as well as the correct dosage, play decisive roles. An effective therapy requires sufficiently
high antibiotic concentrations at the target site over a sufficient period of time.
Obesity is a growing problem worldwide [3] and constitutes a risk factor for the acquisition of
serious infections, as well as for their successful treatment [4]. However, recommended daily doses
of antibiotics are based on pharmacokinetic (PK) studies performed almost exclusively in nonobese
patients [5]. Data to characterize the pharmacokinetics (PK) in obese compared with nonobese patients
are thus increasingly important to assess whether effective meropenem concentrations are reached also
in this growing population. Recent studies indicate that the current standard dosage of meropenem in
obese patients is sufficient [6–8], and there are no recommendations for weight-dependent dosing [9].
However, the majority of these studies use plasma concentrations as the basis for their analyses,
but ideally, also, target site (e.g., tissue) interstitial fluid (ISF) concentrations should be included [10–12].
Only one study with a limited number of obese patients has investigated the plasma, as well as the
tissue PK, of meropenem, but the direct influence of obesity could not be assessed, since no nonobese
control group was implemented [13]. A direct comparison of meropenem tissue concentrations in
obese vs. nonobese patients is still lacking.
We hypothesized that obesity has an influence on the pharmacokinetics of meropenem in plasma
and the ISF of subcutaneous adipose tissue (target site) and investigated whether this might necessitate
dose adjustment. To answer this question, we studied obese and nonobese patients undergoing elective
abdominal surgery in a controlled setting, measuring meropenem concentrations in the plasma, as well
as in subcutaneous tissue, via microdialysis.
2. Results
2.1. Patients
Fifteen obese (two class II and 13 class III) patients scheduled for bariatric surgery and 15 nonobese
patients undergoing elective abdominal surgery, mainly tumour resection (11 patients underwent
gynaecological operations, and the remaining four operations involved the stomach, liver, kidneys
or appendix), were included in the study (see Figure 1—CONSORT flow diagram). The patient
characteristics are presented in Table 1. No patient showed signs of acute infection or critical illness at
the time of the surgery and the first seven postoperative days. No drug-related adverse events were
observed. No interactions between patients’ medications were found to affect the pharmacokinetics
of meropenem.
2.2. Pharmacokinetics
The plasma and ISF data were available from all 30 patients. Free plasma concentrations were
determined in 69 samples. The unbound fraction (f u) was independent of the total concentration and
amounted to 98.3% ± 3.9% (95% CI: 97.4–99.3), with a mean intraindividual coefficient of variation of
2.5%. The difference to 100% was not considered to be clinically relevant, and the total concentrations
were used for the pharmacokinetic/pharmacodynamic (PK/PD) calculations. The mean (total) plasma
concentration–time curve of meropenem was characterized by a lower maximum concentration (Cmax)
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and a smaller slope of the descending trajectory of the concentration–time profile in obese patients
compared with nonobese patients, leading, on average, to an intersection of the curves at about three
hours after infusion (Figure 2).Antibiotics 2020, 9, x 3 of 12 
 
Figure 1. CONSORT flow diagram. BMI = body mass index. 
Table 1. Demographic and clinical characteristics. 
 Obese (n = 15) Nonobese (n = 15) 
Number of females 13 (87%) 13 (87%) 
Age (years) 50.3 ± 9.5 49.5 ± 10.0 
Weight (kg) 134.3 ± 34.3 67.9 ± 8.8 
BMI (kg/m2) 48.7 ± 11.2 23.9 ± 2.1 
Type of surgery   
laparoscopic 15 (100%) 3 (20%) 
open 0 (0%) 12 (80%) 
Length of surgery (h) 2.9 ± 0.6 4.0 ± 1.9 
Serum creatinine (µmol/L) 85.8 ± 26.3 75.3 ± 18.8 
Entries are mean ± standard deviation or numbers (%). BMI = body mass index. 
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Table 1. Demographic and clinical characteristics.
Obese (n = 15) Nonobese (n = 15)
Number of females 13 (87%) 13 (87%)
Age (years) 50.3 ± 9.5 49.5 ± 10.0
Weight (kg) 134.3 ± 34.3 67.9 ± 8.8
BMI (kg/m2) 48.7 ± 11.2 23.9 ± 2.1
Type of surgery
laparoscopic 15 (100%) 3 (20%)
o en 0 ( %) 12 (80%)
Length of surg ry (h) 2.9 ± 0.6 4.0 ± 1.9
Serum creatinine (µmol/L) 85.8 2 .3 75.3 ± 18.8
Entries are mean ± standard deviation or numbers (%). BMI = body mass index.
In two patients, only one catheter was evaluable due to a malfunction of the second catheter.
There was no significant difference between the recovery of the catheters in the right and left arms.
Therefore, the results of both catheters were averaged. The recovery in obese patients was significantly
lower than in the nonobese patients (33.9 vs. 51.2%; 95% CI for the difference was −30.3 to −4.5%,
p = 0.010).
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Table 2. Pharmacokinetic parameters.
Measuerments
Plasma ISF
Obese (n = 15) Nonobese (n = 15) Change in LocationParameter (95% CI) p-Value Obese (n = 15) Nonobese (n = 15)
Change in Location
Parameter (95% CI) p-Value
maximum concentration
(Cmax (mg/L))
54.0 (44.8–58.2) 63.9 (53.6–69.9) −11.0 (−18.3 to −3.5) 0.011 12.6 (6.5–17.1) 18.6 (12.4–31.2) −7.4 (−16.8 to −0.8) 0.026
Timepoint of maximum
(Tmax (h))
0.5 (end of infusion) 0.5 — 1.0 0.75/1.25 a (n = 12/3) 0.75/1.25 a (n = 14/1) — 0.60
Concentration after
8 hours (C8h (mg/L))
1.02 (0.74–1.48) 0.70 (0.48–0.88) 0.33 (−0.03 to 0.72) 0.070 0.54 (0.45–0.77) b 0.36 (0.24–0.51) b 0.21 (0.01–0.38) 0.041
Half-life (t1/2 (h)) c 1.52 (1.44–1.67) 1.31 (1.23–1.43) 0.22 (0.05 to 0.37) 0.0066 1.55 (1.44–1.66) 1.32 (1.14–1.49) 0.24 (−0.02 to 0.42) 0.061
Volume distribution at
steady state (Vss (L))
22.4 (20.7–29.5) 17.6 (16.1–21.0) 5.1 (2.6 to 9.1) 0.0017 — — — —
Clearance (CL(L/h)) 12.5 (9.8–13.9) 11.1 (9.8–12.6) 0.8 (−1.4 to 3.1) 0.46 — — — —
Area under the curve
0 to 8 hours (AUC8h
(mg·h/L))
78.7 (69.1, 99.6) 89.2 (78.1, 100.9) −7.2 (−21.4 to 8.6) 0.35 28.5 (19.2, 44.4) 42.0 (29.7, 66.0) −13.0 (−33.9 to 5.4) 0.15
Area under the curve
extrapolated to infinity
(AUC∞ (mg·h/L)) d
80.3 (71.8–102.0) 90.3 (79.4–102.3) −6.5 (−21.1 to 10.4) 0.46 33.7 (23.6–38.7) 44.6 (29.2–59.1) −11.4 (−31.9 to 5.5) 0.22
Penetration ratio (AUC∞,
ISF/AUC∞, plasma)
— — — 0.35 (0.27–0.52) 0.48 (0.33–0.62) −0.09 (−0.30 to 0.08) 0.40
Entries are median (interquartile range). a Fraction 0.5–1 h and 1–1.5 h, respectively, b to 8.0-h extrapolated concentration. c The median adjusted R-squared of the regressions for the
terminal phases were 0.997 in the plasma and 0.987 in the interstitial fluid (ISF). d The median extrapolated aera under the curve (AUC) was 1.8% in the plasma and 5.9% in the ISF.
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The primary endpoint, the area under the concentration–time curve from zero to eight h (AUC8h)
in the ISF of the subcutaneous adipose tissue, did not differ significantly between obese and nonobese
patients, with median values of 28.5 (obese) vs. 42.0 (nonobese) mg/L·h, with a difference in the location
parameter of −13.0 mg/L·h (95% CI: −33.9 to 5.4 mg/L·h, p = 0.15). The same applied to the AUC
extrapolated to infinity (AUC∞), with median values of 33.7 (obese) vs. 44.6 (nonobese) mg/L·h, with a
difference in the location parameter of −11.4 mg/L·h (95% CI −31.9 to 5.5 mg/L·h, p = 0.22). The Cmax in
the ISF were lower in obese compared with nonobese patients, but the concentration curves crossed at
about four-to-five h (Figure 2). The pharmacokinetic parameters are summarized in Table 2.
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Figure 2. Semilogarithmic concentration–time course (mean and SD) of meropenem in the plasma
and interstitial fluid of subcutaneous tissue in obese or nonobese surgical patients following an
intravenous infusion of 1 g of meropenem. The dotted line indicates the European Committee
on Antimicrobial Susceptibility Testing (EUCAST) breakpoints for Pseudomonas aeruginosa and
Enterobacteriaceae. ISF: interstitial fluid.
Table 3. Time (in hours) for which the concentration is above the minimum inhibitory concentration
(MIC) (T > MIC).
Obese (n = 15) Nonobese (n = 15) Difference between Groups p-Value
Estimate 95% CI Estimate 95% CI Estimate 95% CI
MIC in Plasma
0.25 mg/L 11.9 (10.3 to 13.4) 10.2 (9.3 to 11.2) +1.6 (−0.3 to 3.6) 0.097
2 mg/L 6.9 (6.0 to 7.8) 6.1 (5.5 to 6.8) +0.8 (−0.3 to 2.0) 0.16
8 mg/L 3.8 (3.3 to 4.2) 3.5 (3.1 to 3.9) +0.2 (−0.4 to 0.9) 0.42
MIC in ISF
0.25 mg/L 11.0 (10.1 to 11.8) 9.6 (8.2 to 10.9) +1.4 (−0.3 to 3.0) 0.10
2 mg/L 5.4 (4.7 to 6.1) 5.0 (4.0 to 6.1) +0.3 (−1.0 to 1.7) 0.60
8 mg/L a 1.4 (0.7 to 2.1) 2.0 (1.2 to 2.9) −0.6 (−1.8 to 0.5) 0.26
Entr es a mean and 95% CI. a Five patients from the obese and three from the nonobese group did not reach a MIC
(i.e., time above the MIC was zero).
In the obese group, the Cmax in the plasma was significantly lower, the volume of distribution
at the steady state (Vss) higher and the half-life (t1/2) longer, whereas no significant differences were
found regarding the clearance (CL) or AUC. In the ISF, the results were qualitatively similar, though the
difference in the t1/2 was not significant, whereas the difference in concentration after eight hours (C8h)
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was. The penetration ratio, expressed as AUCISF/AUCplasma, was similar in both groups (median of
0.35 in the obese group and 0.48 in the nonobese group, p = 0.40). The Vss was significantly correlated
with the weight (R = 0.73, 95% CI: 0.51–0.87, p < 0.001, Figure 3). Table 3 shows the T>MIC (time
above the minimum inhibitory concentration) values for pathogens with MICs of 0.25, 2 and 8 mg/L;
there were no significant differences between the obese and nonobese patients.Antibiotics 2020, 9, x 6 of 12 
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3. Discussion
The present study is the first clinical study with a direct comparison of meropenem tissue
concentration in obese vs. nonobese patients. The summarized findings are that the maximum
concentrations in the obese patients were lower than in the nonobese control group, the volume of
distribution was higher, the clearance comparabl and the half-life longer. As an overall net result,
obesity had little or no clinically relevant effect on the PK/PD index T > MIC when evaluating a single
short-term infusion of the standard meropenem dose.
The pharmacokinetics of meropenem in humans has been investigated extensively also for
critically ill patients [14]. The maximum plasma concentrations we found in the control group
agreed well with previous data in healthy volunteers, whereas the half-life was somewhat longer,
and the AUC was correspondingly higher [15]. The differences could be due to the older study
population, with an age-associated decrease in kidney functions [16]. Further, physiological changes
during surgery/anesthesia, such as changes in cardiac output, blood volume, regional blood flow and
extracellular fluid volume, may have influenced the elimination of meropenem [17].
The main finding of the study is that, in direct comparison with nonobese surgical patients,
obese surgical patients have lower maximum concentrations due to a higher volume of distribution but
a similar clearance and, thus, a longer half-life. This might have important implications on alternative
dosing regimens, such as prolonged infusions of meropenem. The lower ISF concentrations during
surgery in obese patients compared with nonobese patients as observed in the present study are in-line
with previously published results and may be explained by a lower subcutaneous adipose tissue
blood flow [18]. However, these effects of obesity are different for individual antibiotics [9], which
Antibiotics 2020, 9, 931 7 of 11
is why these results are only valid for meropenem. For other substances (even quite similar ones,
like doripenem), separate results are needed for evidence-based recommendations.
All PK/PD indices should be referenced to the (nonprotein-bound) fraction (f u) of the drug [19].
For meropenem, the total or free concentrations are equally suitable for calculating the PK/PD
parameters, given the nearly absent plasma protein binding. The f u of 98% as determined in the
present study is commonly accepted as reliable, despite contrasting results in a very recent study
reporting a median f u of 62% (range 42–99%) only [19,20]. However, except that these results are in
contradiction to other studies, no information is provided regarding the validation data of the assay,
including the ultrafiltration procedure, as well as the possibility of the preanalytical degradation of
meropenem [20–22].
The decisive PK/PD parameter for beta-lactams is T>MIC. The plasma and tissue concentrations
remain above the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints
of 2 mg/L for Pseudomonas and Enterobacteriaceae [23] for comparably long periods of time, suggesting
that body weight-adjusted dosages of meropenem in obesity are unnecessary after short-term infusions.
In obese patients, the mean values of the T>MIC were somewhat higher in most cases, though the
difference was not clinically relevant, because a dose reduction for obese patients would not benefit
them clinically. Although the sample size was based on the primary endpoint, the width of the 95% CI
suggests that it was also adequate for the T>MIC. At first glance, the longer T>MIC in obese patients
is a surprising message, considering the lower maximum plasma concentrations in the obese group,
but understandable in the context of the time-dependent and not concentration-dependent antibacterial
activity of beta-lactams. Due to the longer half-life of meropenem though, the concentrations were equal
or even higher in the obese patients. The conclusions of this study are consistent with most previous
studies [5–9,13,24], but our study included the pharmacokinetics in the plasma and tissue concentrations,
as well as a comparison between an age-matched nonobese control group, thereby placing these
conclusions on much firmer ground.
However, this study had some limitations. The study was performed in surgical noninfected
patients under defined conditions. Meropenem is particularly indicated for severe infections and
in intensive care unit (ICU) patients, where confounding factors such as changes in the volume of
distribution, reduced microcirculation or edema exist. The body mass index (BMI) values in the
obese group are very high, and as such, the results may not be entirely applicable in nonbariatric
cohorts. Moreover, by design, patients with BMI 30 to 34.9 kg/m2 were not included to have a clearer
separation between the groups. Since the obese patients did not show any relevant differences to
nonobese patients, it can be assumed that these limitations are minor. Furthermore, surgery and/or
anesthesia may have affected the distribution and elimination rate of meropenem. This could only be
investigated with a control group without surgery/anesthesia and should be investigated in clinical
trials in the future.
4. Materials and Methods
4.1. Study Design and Patients
This prospective, parallel group, open-label, monocentric, controlled trial was embedded in a
larger pharmacokinetic study at the Leipzig University Hospital and was registered in the European
Union clinical trials register (EudraCT No. 2012-004383-22) and German Clinical trials Register
(DRKS00004776). Previous analyses on linezolid and fosfomycin have been already published [25–27].
Approval for the trial was obtained from the Leipzig University Ethics Committee (121/13-28012013)
and the Federal Institute for Drugs and Medical Devices of Germany (BfArM—No.: 4038808). Methods,
design and sample size calculations were described in detail [28]. Patients scheduled for elective
abdominal surgery at Leipzig University Hospital were screened for eligibility. Inclusion criteria
comprised ages ≥ 18 years and body mass index (BMI) ≥ 35 kg/m2 for obese patients or between
18.5 and 30 kg/m2 for nonobese patients. Main exclusion criteria were pregnancy or breastfeeding,
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known allergic reactions to one of the investigated medications or severe liver or kidney diseases.
Prior written informed consent was obtained from all study participants.
4.2. Study Procedure
Microdialysis catheters (CMA 63 microdialysis probe, cut-off 20,000 Da, CMA, Kista, Sweden)
were placed in the subcutaneous adipose tissue of both upper arms without using local anesthesia
(one in each arm) 90 min before beginning general anesthesia and administration of the study drugs.
As a perioperative antibiotic prophylaxis, patients were given a standard (weight-independent) dose of
1000-mg meropenem (Meronem®, AstraZeneca GmbH, Wedel, Germany) in combination with 600-mg
linezolid (Zyvoxid®, Pfizer Deutschland GmbH, Berlin, Germany) as a single 30-min infusion after the
induction of anesthesia (60–30 min prior to incision) through an additional vein access. An analysis
of the linezolid concentrations in these patients was already published separately [25,26] due to the
significantly different properties between the two antibiotics. Anesthesia was performed according to
clinical standards and left at the discretion of the anesthetist. The catheters were constantly perfused
with 0.9% saline at 2 µL/min. Blood samples were taken pre-dose and after 0.5 (end of infusion),
1, 2, 3, 4, 5, 6 and 8 h. Microdialysate samples were collected pre-dose and after dosing at 0 to 0.5,
0.5 to 1, 1 to 1.5, 1.5 to 2, 2 to 3, 3 to 4, 4 to 5, 5 to 6, 6 to 7 and 7 to 8 h. For calibration of the
probes, the recovery of each probe was determined by retrodialysis, with meropenem 20 mg/L in
saline [28,29]. Retroperfusate (CRP) and retrodialysate (CRD) drug concentrations were utilized to
determine the relative recovery (relative recovery = 1 − (CRD/CRP) × 100%). The ISF concentrations
were then determined by CISF = Cmicrodialysate × 100/(relative recovery). Blood samples were centrifuged
within 30 min of sampling (3000× g, 4 ◦C, 10 min). Plasma and microdialysate samples were frozen
immediately at −25 ◦C and then stored at −80 ◦C until analysis. Patients were visited preoperatively,
intraoperatively and daily between postoperative days 1 and 7 or until discharge, as described in the
complete participant timeline [28]. Study data were collected and managed using an Oracle-DBMS
database with the eResearch Network. Electronic data capture tools are hosted at the Clinical Trials
Centre of the University of Leipzig, Germany.
4.3. Drug Analysis
Meropenem concentrations were analyzed adapting a validated high performance liquid
chromatography-ultraviolet (HPLC-UV) method [30]. Sample treatment of plasma, followed a
published protocol for beta-lactams [31]. In brief, plasma (100 µL) was mixed with 25-mM sodium
dihydrogen phosphate (200 µL) and acetonitrile (500 µL). After separation of the precipitated proteins,
the acetonitrile was extracted into dichloromethane (1.3 mL). Sample treatment for the determination of
the free plasma concentration was performed by ultrafiltration. Plasma (300 µL) was buffered with 3-M
potassium phosphate, pH 7.4 (10 µL), incubated (10 min/37 ◦C/1000× g, centrifuge 5417R, Eppendorf,
Hamburg, Germany) and then centrifuged (20 min/37 ◦C/1000× g) using Vivacon 500 ultrafiltration
devices (Sartorius, Göttingen, Germany). Microdialysate was injected directly. The injection volume
was 1–3 µL. Chromatography was performed on a Prominence Modular LC-20 HPLC (Shimadzu,
Duisburg, Germany) with photometric detection at 300 nm. The autosampler was cooled to 6 ◦C,
and the column temperature was maintained at 40 ◦C. The analytical column was a Waters XBridge C18
BEH 2.5 µm 50 × 3 mm (Waters, Eschborn, Germany) or a Macherey-Nagel Nucleoshell RP18 2.7 µm
100 × 3 mm (Macherey-Nagel, Düren, Germany). Both columns were preceded by a Macherey-Nagel
Nucleoshell RP18 2.7 µm 4 × 3-mm column protection system. The mobile phase was 0.1-M sodium
phosphate buffer/acetonitrile 92:8 (v/v) and final pH 2.9–3.1. The flow rate was 0.4 mL/min and the
retention time of meropenem 2.5–4.5 min (depending on the exact pH and column). Based on in-process
quality controls (50, 15 and 0.5 mg/L in plasma or 15, 1.5 and 0.15 mg/L in saline as the surrogate
for microdialysate), the mean intra-/interassay imprecision and inaccuracy were <4%. The accuracy
of free meropenem cannot be specified, as the protein binding and, accordingly, also, the true free
concentration in an individual plasma sample, are not known. The unbound fraction (f u) in the pooled
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plasma from healthy volunteers, analyzed as quality controls with each assay, was 99.5% ± 1.3%.
The lower limit of quantification (LLOQ) was 0.1 mg/L in plasma and 0.02 mg/L in saline.
4.4. Study Endpoints
The primary endpoint was the area under the concentration–time curve from 0 to 8 h (AUC8h)
of meropenem in the ISF. Secondary endpoints were AUC8h in the plasma, maximum concentration
(Cmax), half-life (t1/2), AUCISF/AUCplasma ratio and other pharmacokinetic/pharmacodynamic (PK/PD)
parameters in the ISF and plasma [28]. For the exploratory PK/PD analysis, we used the T>MIC (time
above the minimum inhibitory concentration) [15] with MIC values from 0.25 mg/L to 8 mg/L covering
the EUCAST breakpoints of clinically relevant bacteria [23].
4.5. Pharmacokinetic and Statistical Analysis
The ISF and plasma concentrations were analyzed on a logarithmic scale. Noncompartmental
PK analysis (NCA) was carried out using Phoenix WinNonlin 8.1 (Certara, Princeton, NJ, USA).
The elimination rate constant λz was determined by log-linear regression over the last 3 to 4 data points
(terminal phase) and began typically by 4 h (plasma) or 4.5 h (ISF). The linear-up/log-down trapezoidal
rule was used for calculation of the AUC0–8h. Extrapolation of the AUC to infinity (AUC∞) was based
on the last predicted concentration. The tissue penetration ratio (AUCISF/AUCplasma) was calculated
using the AUC∞. The ISF parameters were first determined separately in each of the two catheters and
then averaged. The software R (The R Foundation, Vienna, Austria, version 3.6.3) was used for the
data visualization and calculation of statistical tests. Comparison between the groups was made using
the Welch t-test or the Wilcoxon Mann-Whitney test. In the first case, differences between means were
provided with a 95% Wald confidence interval, and in the second, a Hodges-Lehmann estimator with
an exact 95% confidence interval was used. p < 0.05 was considered statistically significant.
5. Conclusions
The pharmacokinetics of meropenem in morbidly obese patients was characterized by lower
maximum plasma concentrations and a higher volume of distribution compared with nonobese
patients. Due to the slightly longer half-life, the PK/PD parameter T > MIC of meropenem was not
negatively affected by obesity, and body weight-adjusted dosing seems unnecessary in obese patients
after a short-term infusion.
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